ACOR Share Price

Open 24.90 Change Price %
High 25.15 1 Day -0.10 -0.40
Low 24.35 1 Week -0.40 -1.58
Close 24.90 1 Month 4.70 23.27
Volume 416167 1 Year -8.11 -24.57
52 Week High 37.36
52 Week Low 16.40
ACOR Important Levels
Resistance 2 25.64
Resistance 1 25.34
Pivot 24.80
Support 1 24.46
Support 2 24.16
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
ASTI 0.00 0.00%
WRES 0.09 28.57%
More..
NASDAQ USA Top Gainers Stocks
MYRX 0.10 100.00%
LOCM 0.09 50.00%
CEMP 4.05 28.57%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
IPCI 2.55 18.60%
QKLS 0.15 15.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
GMETP 0.70 -59.54%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Acorda Therapeutics, Inc. (NASDAQ: ACOR)

ACOR Technical Analysis 4
As on 24th Feb 2017 ACOR Share Price closed @ 24.90 and we RECOMMEND Buy for LONG-TERM with Stoploss of 23.68 & Strong Buy for SHORT-TERM with Stoploss of 21.29 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACOR Target for February
1st Target up-side 22.03
2nd Target up-side 23.1
3rd Target up-side 24.17
1st Target down-side 18.97
2nd Target down-side 17.9
3rd Target down-side 16.83
ACOR Other Details
Segment EQ
Market Capital 995115008.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.acorda.com
ACOR Address
ACOR
420 Saw Mill River Road
Ardsley, NY 10502
United States
Phone: 914-347-4300
Fax: 914-347-4560
Interactive Technical Analysis Chart Acorda Therapeutics, Inc. ( ACOR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Acorda Therapeutics, Inc.
ACOR Business Profile
Acorda Therapeutics, Inc. (Acorda), incorporated on March 17, 1995, is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug for the management of spasticity. Ampyra is marketed as Fampyra outside the United States by Biogen Idec International GmbH (Biogen Idec). On February 6, 2012, the Company launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules under an agreement with Watson Pharma, Inc. In December 2012, the Company acquired Neuronex, Inc.